View:
United States securities and exchange commission logo
July 7, 2021
Thomas Zindrick, J.D.
President and Chief Executive Officer
Genelux Corporation
3030 Bunker Hill Street, Suite 300
San Diego, CA 92109
Re: Genelux Corporation
Amendment No. 1 to
Draft Registration Statement on Form S-1
Submitted June 24,
2021
CIK No. 0001231457
Dear Mr. Zindrick:
We have reviewed your amended draft registration statement and have
the following
comment.
Please respond to this letter by providing the requested
information and either submitting
an amended draft registration statement or publicly filing your
registration statement on
EDGAR. If you do not believe our comment applies to your facts and
circumstances or do not
believe an amendment is appropriate, please tell us why in your
response.
After reviewing the information you provide in response to this
comment and your
amended draft registration statement or filed registration statement, we
may have additional
comments.
Amendment No. 1 to Draft Registration Statement on Form S-1 submitted
June 24, 2021
Ovarian Cancer Program, page 114
1. Please disclose the
material assumptions underlying the projections presented in this
section.
Thomas Zindrick, J.D.
FirstName LastNameThomas Zindrick, J.D.
Genelux Corporation
Comapany
July 7, 2021NameGenelux Corporation
July 7,2 2021 Page 2
Page
FirstName LastName
You may contact Tracie Mariner at 202-551-3744 or Vanessa Robertson at
202-551-3649
if you have questions regarding comments on the financial statements and
related
matters. Please contact Jeffrey Gabor at 202-551-2544 or Laura Crotty at
202-551-7614 with
any other questions.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: Amy Hallman Rice, Esq.